SCHEMBL4237447

SCHEMBL4237447

O=c1c2ccccc2nc(-c2ccco2)n1NCc1ccc(Br)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.56
ALDH1A1 P00352 6/20 0.56
TSHR P16473 4/20 0.56
LMNA P02545 4/20 0.56
PKM P14618 1/20 0.56
CASR P41180 1/20 0.54
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
MAPK1 P28482 2/20 0.50
HSD17B10 Q99714 3/20 0.48
HTT P42858 1/20 0.48
MAPT P10636 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
USP2 O75604 2/20 0.47
TP53 P04637 2/20 0.47
ALOX15 P16050 2/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4245035 0.84 EGFR (0.62) SMN1; SMN2ALDH1A1TSHRLMNACYP1A2
SCHEMBL4241395 0.80 CYP1A2 (0.56) SMN1; SMN2ALDH1A1TSHRLMNACYP1A2
SCHEMBL4237311 0.79 ALDH1A1 (0.58) SMN1; SMN2ALDH1A1TSHRLMNACYP1A2
SCHEMBL4237688 0.79 CYP1A2 (0.52) SMN1; SMN2ALDH1A1TSHRLMNACYP1A2
SCHEMBL4233268 0.79 ALDH1A1 (0.58) SMN1; SMN2ALDH1A1TSHRLMNACYP1A2
SCHEMBL4236185 0.79 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1TSHRLMNACYP1A2
SCHEMBL4240585 0.79 CYP1A2 (0.55) SMN1; SMN2ALDH1A1TSHRLMNACYP1A2
SCHEMBL4244207 0.79 MAPT (0.62) SMN1; SMN2ALDH1A1TSHRLMNACYP1A2
SCHEMBL14161015 0.78 KMT2A (0.71) SMN1; SMN2ALDH1A1TSHRLMNACYP1A2
SCHEMBL4238366 0.78 CASR (0.56) SMN1; SMN2ALDH1A1TSHRLMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 SMN1; SMN2 4767/4885ALDH1A1 3192/4885TSHR 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.